Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Galectin Therapeutics Q3 2026 Results: Net Loss of $3.53M, Loss Narrows

Galectin Therapeutics reported a net loss of $17.7 million for the nine months ended September 30, 2026, an improvement from the $25.3 million loss in the prior year period. A significant balance sheet event occurred with the conversion of $105.2 million in debt into common stock, substantially reducing total liabilities and increasing the common shares outstanding to over 100 million.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Net income-3.5-8.2
EPS (diluted, $ a share)$-0.04$-0.13

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: GALT. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Galectin Therapeutics Inc: key numbers

Share price
$3.02Close, Nov 16
Market cap
$305M
Shares outstanding
100.88MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Galectin Therapeutics Inc

All →
7:56 AM ET 8-K
Financial Results

Galectin Therapeutics Financial Results

Galectin Therapeutics reported financial results for the quarter ended September 30, 2026, and provided a business update on its Phase 3 clinical trial protocol for belapectin in MASH cirrhosis. The company reached alignment with the FDA on the Phase 3 trial design and presented positive new analyses from its NAVIGATE trial at the AASLD Annual Meeting.

Term
3 months

“New analyses were presented at AASLD, marking the fourth consecutive major liver conference where Galectin data was included in an oral presentation. We were extremely pleased by the positive feedback received on the oral presentation as well as the two poster presentations and are excited that our data was included in the AASLD conference highlights and the portal hypertension debrief.”

Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics

“As previously disclosed, we submitted our registrational Phase 3 protocol to FDA in the third quarter after reaching alignment on primary elements of the planned Phase 3 trial design. Additional information is expected to be presented at the Annual Stockholders’ Meeting on December 3, 2026.”

Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.